{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:06:17Z","timestamp":1793909177691,"version":"4.8.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022790","name":"Hector Stiftung II","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"Hector Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201908080072"],"award-info":[{"award-number":["201908080072"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108320069"],"award-info":[{"award-number":["202108320069"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.molmed.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T14:15:17Z","timestamp":1739628917000},"page":"755-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Molecular subtypes of intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Alessandro","family":"De Santis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rei\u00dffelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-3177","authenticated-orcid":false,"given":"Sebastian","family":"Sch\u00f6lch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.01.008_bb0005","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.01.008_bb0010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ijc.22283","article-title":"Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case\u2013control study","volume":"120","author":"Welzel","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2025.01.008_bb0015","first-page":"959","article-title":"Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case\u2013control study in Italy","volume":"12","author":"Donato","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.molmed.2025.01.008_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.22606","article-title":"Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans","volume":"49","author":"El-Serag","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/j.gastro.2004.12.048","article-title":"Risk factors of intrahepatic cholangiocarcinoma in the United States: a case\u2013control study","volume":"128","author":"Shaib","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0030","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1572-0241.2008.01796.x","article-title":"Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case\u2013control study","volume":"103","author":"Lee","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3748\/wjg.14.632","article-title":"Risk factors for intrahepatic cholangiocarcinoma: a case\u2013control study in China","volume":"14","author":"Zhou","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0040","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1172\/JCI63065","article-title":"Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes","volume":"122","author":"Sekiya","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.01.008_bb0045","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1349-7006.2004.tb02492.x","article-title":"Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma","volume":"95","author":"Yamamoto","year":"2004","journal-title":"Cancer Sci."},{"key":"10.1016\/j.molmed.2025.01.008_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0055","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.01.008_bb0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0065","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial immune heterogeneity reflects the diverse tumor\u2013immune interactions in intrahepatic cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.01.008_bb0070","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v12.i40.6500","article-title":"Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient","volume":"12","author":"Rattanasinganchan","year":"2006","journal-title":"WJG"},{"key":"10.1016\/j.molmed.2025.01.008_bb0075","doi-asserted-by":"crossref","first-page":"8675","DOI":"10.3390\/ijms22168675","article-title":"Patient-derived organoids of cholangiocarcinoma","volume":"22","author":"Maier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.01.008_bb0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41467-023-35896-4","article-title":"Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.01.008_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41575-022-00739-y","article-title":"Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance","volume":"20","author":"Calvisi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0090","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid models of human liver cancers derived from tumor needle biopsies","volume":"24","author":"Nuciforo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2025.01.008_bb0095","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers12082308","article-title":"Evolution of the experimental models of cholangiocarcinoma","volume":"12","author":"Massa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.01.008_bb0100","doi-asserted-by":"crossref","first-page":"86766","DOI":"10.18632\/oncotarget.13575","article-title":"Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line","volume":"7","author":"Peraldo Neia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2025.01.008_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2016.05.017","article-title":"Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2\u2013CCDC6 fusion protein","volume":"380","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.molmed.2025.01.008_bb0110","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.22088","article-title":"A novel \u201cpatient-like\u201d model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines","volume":"47","author":"Sirica","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0115","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.23729","article-title":"A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells","volume":"52","author":"Fingas","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1007082515548","article-title":"Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide","volume":"208","author":"Al-Bader","year":"2000","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.molmed.2025.01.008_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0163-7258(96)00062-9","article-title":"N-Nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation","volume":"71","author":"Verna","year":"1996","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.01.008_bb0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/carcin\/bgh037","article-title":"Thioaceatamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma","volume":"25","author":"Yeh","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.molmed.2025.01.008_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1541-7786.MCR-13-0503","article-title":"Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development","volume":"12","author":"Lozano","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.molmed.2025.01.008_bb0140","doi-asserted-by":"crossref","first-page":"19513","DOI":"10.1073\/pnas.1311707110","article-title":"Mouse model of intrahepatic cholangiocarcinoma validates FIG\u2013ROS as a potent fusion oncogene and therapeutic target","volume":"110","author":"Saborowski","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molmed.2025.01.008_bb0145","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.01.008_bb0150","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.857140","article-title":"Up-to-date pathologic classification and molecular characteristics of intrahepatic cholangiocarcinoma","volume":"9","author":"Chung","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.molmed.2025.01.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104657","article-title":"DNA methylation-based classifier differentiates intrahepatic pancreato-biliary tumours","volume":"93","author":"Dragomir","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.molmed.2025.01.008_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00428-018-02511-7","article-title":"DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype","volume":"475","author":"Kim","year":"2019","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0170","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1007\/s13277-015-3261-1","article-title":"Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis","volume":"36","author":"Xue","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3350\/cmh.2018.0067","article-title":"Pathologic differential diagnosis of metastatic carcinoma in the liver","volume":"25","author":"Park","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0180","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.hpb.2018.07.021","article-title":"Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma","volume":"21","author":"Akita","year":"2019","journal-title":"HPB"},{"key":"10.1016\/j.molmed.2025.01.008_bb0185","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/his.13127","article-title":"Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss","volume":"70","author":"Misumi","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0190","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/PAS.0000000000001118","article-title":"Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns","volume":"42","author":"Sigel","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0195","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3390\/cancers14133156","article-title":"Integrative analysis of intrahepatic cholangiocarcinoma subtypes for improved patient stratification: clinical, pathological, and radiological considerations","volume":"14","author":"Ts","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.molmed.2025.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","article-title":"Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma","volume":"13","author":"Song","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.01.008_bb0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/his.13633","article-title":"Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas","volume":"73","author":"Sawada","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0215","series-title":"PDQ Cancer Information Summaries","article-title":"Bile duct cancer (cholangiocarcinoma) treatment: patient version","author":"National Cancer Institute","year":"2002"},{"key":"10.1016\/j.molmed.2025.01.008_bb0220","series-title":"NCCN guidelines. Biliary tract cancers","author":"National Comprehensive Cancer Network (NCCN)","year":"2024"},{"key":"10.1016\/j.molmed.2025.01.008_bb0225","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.molmed.2025.01.008_bb0230","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.01.008_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0240","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0245","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.molmed.2025.01.008_bb0250","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0255","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2025.01.008_bb0260","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/onco.13844","article-title":"Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns","volume":"26","author":"Israel","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2025.01.008_bb0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.01.008_bb0270","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.01.008_bb0275","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0280","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0285","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.01.008_bb0290","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0295","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2025.01.008_bb0300","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4079","article-title":"Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: final results from the phase 2 SUMMIT basket trial","volume":"40","author":"Harding","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2025.01.008_bb0310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.2021.39.3_suppl.299","article-title":"Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2025.01.008_bb0315","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0320","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0325","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0330","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.molmed.2025.01.008_bb0335","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2022.40.4_suppl.427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2025.01.008_bb0340","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/bjc.2017.119","article-title":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma","volume":"116","author":"Shroff","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2025.01.008_bb0345","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Hawkins","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2025.01.008_bb0350","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cancers12071975","article-title":"Treatment of patients with advanced biliary tract cancer with either oxaliplatin, gemcitabine, and capecitabine or cisplatin and gemcitabine\u2014a randomized phase II trial","volume":"12","author":"Markussen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.molmed.2025.01.008_bb0355","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0360","first-page":"4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): results from a randomized phase II trial","volume":"41","author":"Hawkins","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.molmed.2025.01.008_bb0365","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14737159.2023.2205588","article-title":"Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features","volume":"23","author":"Chen","year":"2023","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.molmed.2025.01.008_bb0370","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/hep.25595","article-title":"Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes","volume":"55","author":"Komuta","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2025.01.008_bb0375","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/cancers13122871","article-title":"Histological heterogeneity of primary liver cancers: clinical relevance, diagnostic pitfalls and the pathologist\u2019s role","volume":"13","author":"Komuta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.molmed.2025.01.008_bb0380","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/modpathol.2017.22","article-title":"Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas","volume":"30","author":"Akita","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0385","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0390","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0395","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4254\/wjh.v12.i12.1148","article-title":"Molecular heterogeneity in intrahepatic cholangiocarcinoma","volume":"12","author":"Ahn","year":"2020","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0400","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/PAS.0000000000001006","article-title":"MDM2 amplification in intrahepatic cholangiocarcinomas","volume":"42","author":"Kim","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.molmed.2025.01.008_bb0405","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2025.01.008_bb0410","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"KrasG12D and p53 mutation cause primary intrahepatic cholangiocarcinoma","volume":"72","author":"O\u2019Dell","year":"2012","journal-title":"Cancer Res."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:47:40Z","timestamp":1755100060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1471491425000085"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.01.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular subtypes of intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}